Tag Archives: Difei Yang

Revance Therapeutics (RVNC) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $34.00. The company’s shares closed last Monday at $12.70, close to its 52-week low of $9.88. According

Zogenix (ZGNX) Gets a Buy Rating from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix (ZGNX – Research Report) today and set a price target of $65.00. The company’s shares closed last Monday at $42.41. According to TipRanks.com, Yang is a 3-star analyst with

Mizuho Securities Keeps Their Hold Rating on Abeona Therapeutics (ABEO)

In a report released today, Difei Yang from Mizuho Securities maintained a Hold rating on Abeona Therapeutics (ABEO – Research Report), with a price target of $4. The company’s shares closed last Monday at $2.90, close to its 52-week low

Mizuho Securities Remains a Buy on Xeris Pharmaceuticals Inc (XERS)

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals Inc (XERS – Research Report), with a price target of $27. The company’s shares closed last Monday at $11.60. Yang commented: “We applied

Analysts Are Bullish on Top Healthcare Stocks: Zogenix (ZGNX), Stryker Corporation (SYK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zogenix (ZGNX – Research Report), Stryker Corporation (SYK – Research Report) and Global Blood Therapeutics (GBT – Research Report) with bullish sentiments.

Abeona Therapeutics (ABEO) Receives a Hold from Mizuho Securities

In a report released yesterday, Difei Yang from Mizuho Securities reiterated a Hold rating on Abeona Therapeutics (ABEO – Research Report), with a price target of $4. The company’s shares closed last Monday at $2.94, close to its 52-week low